On Tuesday, Shares of Applied Materials, Inc. (NASDAQ:AMAT), SUBTRACT -2.52% and closed at $28.64 in the last trading session. The last trading range of the stock ranges between $28.31 and $29.39. The company’s Market capitalization is $30.57 Billion with the total Outstanding Shares of 1.08Billion. During the 52-week trading session the minimum price at which share price traded, registered at $15.07 and reached to max level of $31.07. Applied Materials, Inc. provides manufacturing equipment, services, and software to the semiconductor, display, solar photovoltaic (PV), and related industries worldwide. It operates through four segments: Silicon Systems, Applied Global Services, Display, and Energy and Environmental Solutions. The Silicon Systems segment develops, manufactures, and sells a range of manufacturing equipment used to fabricate semiconductor chips or integrated circuits. Its products and technologies for transistor and interconnect fabrication, counting epitaxy, ion implantation, oxidation and nitridation, rapid thermal processing, chemical vapor deposition, physical vapor deposition, chemical mechanical planarization, electrochemical deposition, atomic layer deposition, etch, and metrology and inspection, in addition to systems that facilitates transfer of patterns used in the photolithography. The Applied Global Services segment provides solutions to enhance the performance and productivity of semiconductor, display, and solar products. The Display segment offers products for manufacturing liquid crystal displays, organic light-emitting diodes, and other display technologies for televisions, personal computers, tablets, smartphones, and other consumer-oriented devices.
Novavax, Inc. (NASDAQ:NVAX), DROPPED -5.85% and closed at $1.77 in the last trading session. The last trading range of the stock ranges between $1.77 and $1.93. The company’s Market capitalization is $501.34 Million with the total Outstanding Shares of 271.19 Million. During the 52-week trading session the minimum price at which share price traded, registered at $1.16 and reached to max level of $9.23. Novavax, Inc., (NVAX) recently declared it has replanned its 4th annual Shareholder and Analyst Meeting. The Company will host an Shareholder and Analyst update as part of its third quarter financial results conference call and webcast on Wednesday, November 9, 2016.
“We continue to analyze data from our Resolve clinical trial and map out the clinical path forward for our older adult RSV F Vaccine in the context of our other clinical programs,” said Stanley C. Erck, President and CEO. “We would like to finalize those plans and communicate them at the same time as our third quarter financial results call in early November. We look forward to providing the next steps in our RSV F Vaccine program, in addition to an update on the path forward for additional programs in our pipeline and our financial and operating plan, which we will provide as a dedicated part of our November financial results.”